Cox-2 expression and Checkpoint Inhibitor Therapy
Research type
Research Study
Full title
Exploratory analysis of the association between Cyclooxygenase-2 expression and primary resistance to check-point inhibitor therapy for cancer.
IRAS ID
287919
Contact name
Olusola Faluyi
Contact email
Sponsor organisation
The Clatterbridge Cancer Centre NHS Foundation Trust
Duration of Study in the UK
1 years, 9 months, 23 days
Research summary
Treatment with certain drugs called checkpoint inhibitors (CKI) has emerged as an effective form of anti-cancer treatment over the past decade. These drugs block one important way by which cancer prevents the body’s own immune system from attacking it. However, not everyone with cancer benefits. Consequently, it seems important to determine why it is effective treatment in some patients with cancer and not in others. On these grounds, scientists are now looking into other mechanisms which can prevent the body’s immune system from attacking cancer. Furthermore, whether CKI treatment may be ineffective in some cancer patients due to such alternative mechanisms being operational in their cancer. This study is looking at whether levels of a protein called Cyclo-oxygenase-2 (Cox-2) which suppresses the body’s immune reaction are higher in tumours which do not to respond to CKI therapy. Furthermore, what sort of immune differences occur in tumours with higher Cox-2.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
21/NE/0008
Date of REC Opinion
25 Feb 2021
REC opinion
Further Information Favourable Opinion